One‐year clinical experience on the use of Nintedanib in systemic sclerosis

We reviewed 11 patients with systemic sclerosis‐related ILD who were referred to our Scleroderma Unit from January 2020 to January 2021 and started Nintedanib. Non‐specific interstitial pneumonia (NSIP) was prevalent (45%), usual interstitial pneumonia (UIP) and UIP/NSIP pattern were both 27%. Only...

Descripción completa

Detalles Bibliográficos
Autores principales: Magnani, Luca, Spinella, Amelia, Testoni, Sofia, Lumetti, Federica, Scelfo, Chiara, Dardani, Lucia, Bajocchi, Gianluigi, Clini, Enrico, Salvarani, Carlo, Giuggioli, Dilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2023
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203787/
https://www.ncbi.nlm.nih.gov/pubmed/37229296
http://dx.doi.org/10.1002/rcr2.1120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203787/
https://www.ncbi.nlm.nih.gov/pubmed/37229296
http://dx.doi.org/10.1002/rcr2.1120

Ejemplares similares